Targeted cancer therapy and its ophthalmic side effects: A review

Shruthi Harish Bindiganavile; Nita Bhat; Andrew G. Lee; Dan S. Gombos; Nagham Al-Zubidi

doi:10.36401/JIPO-20-21

Targeted cancer therapy and its ophthalmic side effects: A review

Shruthi Harish Bindiganavile, Nita Bhat, Andrew G. Lee, Dan S. Gombos, Nagham Al-Zubidi

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.

Original language	English (US)
Pages (from-to)	6-15
Number of pages	10
Journal	Journal of Immunotherapy and Precision Oncology
Volume	4
Issue number	1
DOIs	https://doi.org/10.36401/JIPO-20-21
State	Published - 2021

Keywords

Cancer immunotherapy
Immune-related adverse events
Ocular side effects

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Cancer Research

Access to Document

10.36401/JIPO-20-21

Cite this

@article{7faca312fa0d44c3a8a34de673fd00ab,

title = "Targeted cancer therapy and its ophthalmic side effects: A review",

abstract = "Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.",

keywords = "Cancer immunotherapy, Immune-related adverse events, Ocular side effects",

author = "Bindiganavile, {Shruthi Harish} and Nita Bhat and Lee, {Andrew G.} and Gombos, {Dan S.} and Nagham Al-Zubidi",

note = "Publisher Copyright: {\textcopyright} Innovative Healthcare Institute.",

year = "2021",

doi = "10.36401/JIPO-20-21",

language = "English (US)",

volume = "4",

pages = "6--15",

journal = "Journal of Immunotherapy and Precision Oncology",

issn = "2666-2345",

publisher = "Innovative Healthcare Institute",

number = "1",

}

TY - JOUR

T1 - Targeted cancer therapy and its ophthalmic side effects

T2 - A review

AU - Bindiganavile, Shruthi Harish

AU - Bhat, Nita

AU - Lee, Andrew G.

AU - Gombos, Dan S.

AU - Al-Zubidi, Nagham

N1 - Publisher Copyright: © Innovative Healthcare Institute.

PY - 2021

Y1 - 2021

N2 - Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.

AB - Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the ocular side effects of targeted cancer therapy agents.

KW - Cancer immunotherapy

KW - Immune-related adverse events

KW - Ocular side effects

UR - http://www.scopus.com/inward/record.url?scp=85102470441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102470441&partnerID=8YFLogxK

U2 - 10.36401/JIPO-20-21

DO - 10.36401/JIPO-20-21

M3 - Review article

AN - SCOPUS:85102470441

SN - 2666-2345

VL - 4

SP - 6

EP - 15

JO - Journal of Immunotherapy and Precision Oncology

JF - Journal of Immunotherapy and Precision Oncology

IS - 1

ER -

Targeted cancer therapy and its ophthalmic side effects: A review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this